RAC1 and cancer: Kaplan–Meier survival analyses showed that patients with RAC1-amp/gain tumors (n = 4005) in the TCGA Pan-Cancer cohort had significantly poorer overall survival (OS) and progression-free survival (PFS) when compared with patients having RAC1-diploidy tumors (n = 6053; log-rank test, p < 0.05; Figure 1A).